Study record · Orforglipron
ACHIEVE-1: orforglipron in early type 2 diabetes
HbA1c fell by about 1.24-1.48 percentage points versus 0.41 with placebo; weight fell up to 7.6% versus 1.7% placebo.
Key result
HbA1c fell by about 1.24-1.48 percentage points versus 0.41 with placebo; weight fell up to 7.6% versus 1.7% placebo.
Study details
Study designRandomized, double-blind, placebo-controlled trial
PhasePhase III
PopulationAdults with type 2 diabetes managed with diet and exercise
Sample size559
RouteOral
Regimen / exposure3, 12 or 36 mg once daily in the trial formulation
Duration40 weeks
ComparatorPlacebo
Primary endpoint / questionChange in HbA1c; body weight secondary endpoint
Safety resultMostly mild-to-moderate GI events; discontinuation due to adverse events occurred more often with active drug.
Key limitationsStudy population had early T2D; approved U.S. obesity indication and current commercial dosing are separate label questions.
Registry / identifierNCT05971940